Show simple item record

Files in this item

Thumbnail

Item metadata

dc.contributor.authorBadu, Kingsley
dc.contributor.authorOyebola, Kolapo
dc.contributor.authorZahouli, Julien Z.B.
dc.contributor.authorFagbamigbe, Adeniyi F.
dc.contributor.authorde Souza, Dziedzom K.
dc.contributor.authorDukhi, Natisha
dc.contributor.authorAmankwaa, Ebenezer F.
dc.contributor.authorTolba, Mai F.
dc.contributor.authorSylverken, Augustina A.
dc.contributor.authorMosi, Lydia
dc.contributor.authorMante, Priscilla Kolibea
dc.contributor.authorMatoke-Muhia, Damaris
dc.contributor.authorGoonoo, Nowsheen
dc.date.accessioned2021-07-16T14:30:10Z
dc.date.available2021-07-16T14:30:10Z
dc.date.issued2021-06-17
dc.identifier275078899
dc.identifier993539d9-f194-4032-ae5e-42dd84c3ef2b
dc.identifier000669990800001
dc.identifier.citationBadu , K , Oyebola , K , Zahouli , J Z B , Fagbamigbe , A F , de Souza , D K , Dukhi , N , Amankwaa , E F , Tolba , M F , Sylverken , A A , Mosi , L , Mante , P K , Matoke-Muhia , D & Goonoo , N 2021 , ' SARS-CoV-2 viral shedding and transmission dynamics : implications of WHO COVID-19 discharge guidelines ' , Frontiers in Medicine , vol. 8 , 648660 . https://doi.org/10.3389/fmed.2021.648660en
dc.identifier.issn2296-858X
dc.identifier.otherRIS: urn:687F594A34E021F4AD7FECEE8111B0B6
dc.identifier.urihttps://hdl.handle.net/10023/23597
dc.descriptionThis work was supported through the Alliance for Accelerating Excellence in Science in Africa (AESA), a funding, agenda-setting, programme management initiative of the African Academy of Sciences (AAS), the African- Union Development Agency (AUDA-NEPAD), founding and funding global partners and through a resolution of the summit of African Union Heads of Governments.en
dc.description.abstractThe evolving nature of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has necessitated periodic revisions of COVID-19 patient treatment and discharge guidelines. Since the identification of the first COVID-19 cases in November 2019, the World Health Organization (WHO) has played a crucial role in tackling the country-level pandemic preparedness and patient management protocols. Among others, the WHO provided a guideline on the clinical management of COVID-19 patients according to which patients can be released from isolation centers on the 10th day following clinical symptom manifestation, with a minimum of 72 additional hours following the resolution of symptoms. However, emerging direct evidence indicating the possibility of viral shedding 14 days after the onset of symptoms called for evaluation of the current WHO discharge recommendations. In this review article, we carried out comprehensive literature analysis of viral shedding with specific focus on the duration of viral shedding and infectivity in asymptomatic and symptomatic (mild, moderate, and severe forms) COVID-19 patients. Our literature search indicates that even though, there are specific instances where the current protocols may not be applicable ( such as in immune-compromised patients there is no strong evidence to contradict the current WHO discharge criteria.
dc.format.extent11
dc.format.extent301088
dc.language.isoeng
dc.relation.ispartofFrontiers in Medicineen
dc.subjectCOVID19en
dc.subjectViral sheddingen
dc.subjectDischarge recommendationsen
dc.subjectTransmission dynamicsen
dc.subjectSARS-CoV-2en
dc.subjectRA0421 Public health. Hygiene. Preventive Medicineen
dc.subjectT-NDASen
dc.subjectSDG 3 - Good Health and Well-beingen
dc.subject.lccRA0421en
dc.titleSARS-CoV-2 viral shedding and transmission dynamics : implications of WHO COVID-19 discharge guidelinesen
dc.typeJournal articleen
dc.contributor.institutionUniversity of St Andrews. Population and Behavioural Science Divisionen
dc.contributor.institutionUniversity of St Andrews. School of Medicineen
dc.identifier.doi10.3389/fmed.2021.648660
dc.description.statusPeer revieweden


This item appears in the following Collection(s)

Show simple item record